Johnson & Johnson (JNJ)
JNJNYSEBiotechnology: Pharmaceutical Preparations
$282.65
+6.43 (+2.33%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $679.13bn
- P/E
- 26.5
- EPS, last 4 quarters
- $10.65
- Dividend yield
- –
- Day range
- –
- 52-week range
- $185.12 to $282.02
- Average volume
- 6.43m
- Previous close
- $276.22
Analysts
17 coveringBuy11 buy, 6 hold, 0 sell
Targets a year out average $287.88, +1.9% from here
Earnings
next estimate $2.91Next report
Dec 2025
+1.2%
Mar 2026
+1.1%
Jun 2026
+2.1%
Sep 2026
+2.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $24.56bn | $24.06bn | $25.31bn | $25.40bn |
| Gross profit | $16.60bn | $15.96bn | $17.26bn | $17.30bn |
| Operating income | $5.43bn | $6.33bn | $7.14bn | $5.84bn |
| Net income | $5.12bn | $5.24bn | $5.53bn | $210.00m |
Last four quarters: revenue $99.33bn, margin 16.2%, free cash flow $20.59bn
News
8 latest- Q3 Earnings Season Winners: 3 Companies Raising GuidanceZacks · 2 hours ago
- ISRG Gains 7.8% in 6 Months: Will the Share Price Recovery Continue?Zacks · 8 hours ago
- Johnson & Johnson Reports Early Clinical Data For Pasritamig, JNJ-9401 In Advanced Prostate Cancer RTTNews · 18 hours ago
- J&J Reports Strong Phase 1 Results For Dual Bispecific Antibody Regimen In Prostate Cancer RTTNews · 1 day ago
- 4 Stocks I'm Not Selling Even If the Fed Keeps Raising RatesThe Motley Fool · 3 days ago
- JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent LossesZacks · 3 days ago
- Halozyme Stock Down Despite Q3 Earnings and Revenue BeatZacks · 3 days ago
- J&J's RYBREVANT FASPRO Approved By FDA For Advanced Head And Neck Cancer; Stock Down RTTNews · 3 days ago
The company
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- jnj.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.